Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer

SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / October 1, 2019 / Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the acceptance of an abstract highlighting data from the AWARE-1 study to be presented at the Society for Immunotherapy of Cancer (SITC). The 34th Annual SITC Meeting will be held November 6-10, 2019 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

The abstract, A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1), was authored by AWARE-1 principal investigator, Aleix Prat, et al. Dr. Prat is Head of Medical Oncology at the Hospital Clínic of Barcelona, Associate Professor of the University of Barcelona and the Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and member of Oncolytics’ Scientific Advisory Board.

Abstracts will be published on the SITC 2019 website at 8:00 a.m. ET on Tuesday, November 5, 2019.

The poster will be presented on Friday, November 8 between 7:00 a.m. and 8:00 p.m. ET.

About Pelareorep

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype – turning “cold” tumors “hot” – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements, including the Company’s belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated developments in the Company’s business and technologies involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Company Contact

Michael Moore
Vice President, Investor Relations & Corporate Communications
858-886-7813
mmoore@oncolytics.ca

Investor Relations

Timothy McCarthy
LifeSci Advisors
212.915.2564
tim@lifesciadvisors.com

Media Contact

Jason Spark
Canale Communications
619-849-6005
jason@canalecomm.com

SOURCE: Oncolytics Biotech Inc.

View source version on accesswire.com:
https://www.accesswire.com/561342/Oncolytics-BiotechR-Announces-Abstract-to-be-Presented-at-the-34th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer